V Bryan Lawlis Sells 2,150 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 2,150 shares of the business’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $89.76, for a total transaction of $192,984.00. Following the transaction, the director now owns 21,310 shares in the company, valued at $1,912,785.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of BMRN traded up $0.81 during trading hours on Friday, reaching $83.16. 2,067,788 shares of the company traded hands, compared to its average volume of 1,089,302. The firm has a market capitalization of $14.83 billion, a P/E ratio of -252.00 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.92 and a current ratio of 3.93. BioMarin Pharmaceutical Inc. has a 1-year low of $79.13 and a 1-year high of $106.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, February 21st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.07. BioMarin Pharmaceutical had a negative net margin of 5.18% and a negative return on equity of 2.79%. The firm had revenue of $353.00 million during the quarter, compared to analyst estimates of $377.35 million. During the same quarter in the prior year, the business posted $0.03 earnings per share. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. As a group, equities analysts forecast that BioMarin Pharmaceutical Inc. will post 0.02 earnings per share for the current year.

BMRN has been the subject of a number of recent research reports. Zacks Investment Research cut shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, December 31st. Cantor Fitzgerald reiterated a “buy” rating and issued a $131.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, April 2nd. Wedbush set a $127.00 price objective on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, February 26th. Oppenheimer set a $92.00 price objective on shares of BioMarin Pharmaceutical and gave the stock a “hold” rating in a report on Tuesday, January 8th. Finally, BidaskClub upgraded shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday, February 28th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $114.82.

Large investors have recently bought and sold shares of the stock. United Services Automobile Association raised its position in BioMarin Pharmaceutical by 4.2% in the fourth quarter. United Services Automobile Association now owns 72,686 shares of the biotechnology company’s stock worth $6,189,000 after purchasing an additional 2,903 shares in the last quarter. Hsbc Holdings PLC grew its stake in BioMarin Pharmaceutical by 24.9% during the fourth quarter. Hsbc Holdings PLC now owns 275,769 shares of the biotechnology company’s stock worth $23,480,000 after buying an additional 55,006 shares during the last quarter. Gateway Investment Advisers LLC grew its stake in BioMarin Pharmaceutical by 41.6% during the fourth quarter. Gateway Investment Advisers LLC now owns 19,644 shares of the biotechnology company’s stock worth $1,673,000 after buying an additional 5,772 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in BioMarin Pharmaceutical by 10.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,104,446 shares of the biotechnology company’s stock worth $94,043,000 after buying an additional 106,391 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its stake in BioMarin Pharmaceutical by 136.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 16,717 shares of the biotechnology company’s stock worth $1,423,000 after buying an additional 9,650 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This report was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/biomarin-pharmaceutical-inc-bmrn-director-v-bryan-lawlis-sells-2150-shares-of-stock.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Recommended Story: What is a Buy-Side Analyst?

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.